Status:

RECRUITING

Power Versus Temperature Controlled Ablation for Treatment of VT

Lead Sponsor:

University Hospitals Coventry and Warwickshire NHS Trust

Collaborating Sponsors:

Medtronic

Coventry University

Conditions:

Ventricular Tachycardia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Ventricular Tachycardia (VT) is a life threatening heart rhythm that comes from the bottom chambers of the heart (the ventricles) and is a leading cause of sudden cardiac death. The majority of patie...

Detailed Description

This trial compares 2 different types of ablation catheter for the treatment of ventricular tachycardia (VT). VT is a life threatening heart rhythm that comes from the bottom chambers of the heart (th...

Eligibility Criteria

Inclusion

  • ≥ 18 years of age to give informed consent specific to national legal requirements.
  • Subject with 1 of the following:
  • Symptomatic VT (despite optimal medical therapy), 3 or more episodes of VT within 24 h (VT storm).
  • At least 3 episodes of VT requiring anti-tachycardia pacing (ATP)
  • At least one appropriate ICD shock.
  • Referred for VT ablation by Consultant Electrophysiologist
  • Subject discussed at cardiac EP MDT
  • Suitable candidate for intra-cardiac mapping and ablation of arrhythmia.
  • Subject agrees to comply with study procedures and be available for routine follow up visits for at least 12 months after enrolment.
  • Subject is willing and able to provide written consent

Exclusion

  • BMI \>40kg/m2
  • Presence of intramural thrombus, tumour or abnormality that precludes vascular access, catheter introduction or manipulations.
  • Coagulopathy, bleeding diathesis or suspected pro-coagulant state.
  • Sepsis, active systemic infection or fever (\>100.5 F/38 C) within a week prior to the ablation procedure.
  • Significant restrictive or obstructive pulmonary disease or chronic respiratory condition.
  • Renal failure requiring dialysis or renal compromise that in the investigators judgement would increase risk to the subject or deem the subject inappropriate to participate in the study.
  • Known allergies or intolerance to anticoagulant and antiplatelet therapies to be used in conjunction with the study or contrast sensitivity that can't be adequately pre-treated prior to the ablation procedure.
  • Positive pregnancy test results for female subjects of childbearing or potential or breast feeding.
  • Enrolment in a concurrent clinical study that in the judgement of the investigator would increase risk to the subject or deem the subject inappropriate to participate in the study.
  • Significant GI bleed.

Key Trial Info

Start Date :

September 26 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2026

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT06028919

Start Date

September 26 2022

End Date

March 1 2026

Last Update

September 19 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University Hospital Coventry and Warwickshire NHS Trust

Coventry, West Midlands, United Kingdom, CV22DX

2

University Hospitals Sussex NHS Foundation Trust

Brighton, United Kingdom, BN2 1ES